Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Adds Reps In Face Of Big Pharma Cuts, Citing Pipeline, Portfolio

Executive Summary

Novartis' decision to expand its sales force by 1,000 reps in the U.S. - in the face of cuts by many of its competitors - reflects the growth potential of the firm's product portfolio and the strength of its pipeline, Pharmaceuticals CEO Thomas Ebeling said

You may also be interested in...



Novartis Gets By With A Little Help From Its Hypertension Franchise

Novartis is still counting on the strength of its pipeline and upcoming product launches to carry the firm through a period of slow growth despite the detrimental impact of the suspension of Zelnorm marketing and the entry of generic competition for Lotrel, the firm stressed during its July 17 second quarter earnings call

Novartis Gets By With A Little Help From Its Hypertension Franchise

Novartis is still counting on the strength of its pipeline and upcoming product launches to carry the firm through a period of slow growth despite the detrimental impact of the suspension of Zelnorm marketing and the entry of generic competition for Lotrel, the firm stressed during its July 17 second quarter earnings call

Biogeneric Bill Has “Reasonable Chance” In ’07 – Barr; More CEOs Unplugged

Barr optimistic about biogenerics in 2007: There is "a reasonable chance for passage" of follow-on biologics legislation in 2007, Barr CEO Bruce Downey says during Morgan Stanley CEOs Unplugged conference in New York Jan. 3. "I would suspect that with the change in the composition of the Congress that we will have hearings on that legislation both in the House and in the Senate," he adds, noting that he expects Rep. Henry Waxman (D-Calif.) to reintroduce follow-on protein legislation during the first two weeks of the new Congress, which was sworn in Jan. 4. Waxman, along with Sens. Chuck Schumer (D-N.Y.) and Hillary Rodham Clinton (D-N.Y.), introduced legislation in October that would grant FDA authority to approve comparable or interchangeable follow-on biologics (1"The Pink Sheet" Oct. 9, 2006, p. 5). If a bill is not passed in 2007, Downey said legislation is unlikely in 2008 due to the presidential election, but he "would certainly expect to see legislation by the end of 2009"...

Related Content

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel